GLP-1s, Your Gallbladder, and Your Pancreas: What the Trials Actually Show

Gallbladder disease and pancreatitis are both listed on the Wegovy and Zepbound labels under Warnings and Precautions, not buried in a footnote — and both have a real, quantifiable trial signal behind them. Here is what the data actually says, separated from the noise.

Gallbladder disease: the labeled numbers

Wegovy's FDA label states plainly that treatment "is associated with an increased occurrence of cholelithiasis and cholecystitis" — gallstones and gallbladder inflammation³. The trial numbers: in randomized clinical trials for weight reduction, cholelithiasis was reported by 1.6% of Wegovy injection-treated patients versus 0.7% of placebo patients, and by 2.5% of Wegovy tablet-treated patients versus 1% of placebo-tablet patients³. That is roughly double the background rate in both formulations — a real, measurable increase, though still an uncommon event overall. A 2023 systematic review and meta-analysis focused specifically on tirzepatide found a comparable pattern of elevated gallbladder and biliary disease risk relative to placebo across its trial program².

**Why this happens is reasonably well understood, and it is not really about the drug's mechanism — it is about the weight loss.** Rapid weight loss from any cause, including diet, bariatric surgery, or a GLP-1, increases gallstone formation, because losing weight quickly shifts cholesterol saturation in bile. This is a known effect of fast weight loss generally; GLP-1s did not invent the phenomenon, they just produce fast enough weight loss to trigger it at a meaningfully higher rate than a typical diet would.

Pancreatitis: a labeled warning, and a real but different kind of signal

Both labels warn that acute pancreatitis — including rare fatal or severe hemorrhagic/necrotizing cases — has been observed in patients on GLP-1 receptor agonists, and both instruct discontinuing the drug if pancreatitis is suspected³. Unlike gallbladder disease, the pancreatitis signal has been harder to pin down at the population level: a large 2025 systematic review and meta-analysis of GLP-1 gastrointestinal adverse events in *Gastroenterology* found an elevated risk of biliary disease consistent with the gallbladder data above, while noting that the pancreatitis signal specifically is smaller and less consistent across studies than the gallbladder one¹. The honest read: pancreatitis is a real, labeled risk that every prescriber should watch for, but the strength of the population-level evidence for it is weaker than for gallstones — the label warning reflects an abundance of caution around a serious, if apparently uncommon, event, not a settled large-effect finding.

The warning signs worth knowing

For gallbladder disease: sudden, severe pain in the upper right abdomen, especially after eating, sometimes radiating to the back or shoulder, along with nausea or fever. For pancreatitis: persistent or severe abdominal pain — the label specifically notes it can radiate to the back — which may or may not come with nausea or vomiting³. Either set of symptoms, especially if severe or persistent, is a reason to contact your prescriber or seek care promptly rather than waiting it out, since both conditions can escalate.

Who should be more cautious

If you have a personal history of gallstones or pancreatitis, this is a conversation to have with your prescriber before starting, not after symptoms appear — it is exactly the kind of history a genuine intake should surface, which is one of the checks in our provider checklist. It is also a reason titration pace matters: slower, label-consistent dose escalation moderates the rate of weight loss, which may in turn moderate gallstone risk, even though this specific link has not been directly proven in a trial. Our titration planner lays out the labeled escalation schedule week by week if you want to check your own pace against it.

The bottom line

Gallbladder disease risk is real, roughly doubled versus placebo, and well-documented in the label's own trial numbers. Pancreatitis is a real labeled warning with a weaker population-level signal behind it. Neither is a reason to avoid a GLP-1 outright for most people, but both are reasons a provider with real clinical oversight — not a rubber-stamp intake — is worth insisting on, which is exactly what prescriber access measures in our Verdict Score methodology. Compare providers on that basis in the ranked reviews.

This is editorial information, not medical advice. Discuss your personal history of gallbladder or pancreatic disease with a licensed clinician before starting a GLP-1, and seek care promptly for severe or persistent abdominal pain.